The successful method of replacing human regular insulin with short-acting insulin analog lispro: Treatment with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

Susumu Ogawa, Kazuhisa Takeuchi, Tsuneo Ishizuka, Taro Kato, Sadayoshi Ito, Yoshitomo Oka

Research output: Contribution to journalArticle

Abstract

Objectives To establish the method of replacing human regular insulin (R) with short-acting insulin analog lispro (LP), and to examine the effects of the replacement on postprandial glycemic control. Methods We examined ten diabetic patients who had been treated with intensive insulin therapy. We measured the plasma glucose levels before a 400kcal meal, and 30-, 60-, 90-, 120-, 180-, 240- and 360-min postprandial plasma glucose levels (PPG). R, as well as various doses of LP (100%, 75%, 50% 25% of R dose) were tried before the meal. Various doses of NPH were added with LP before the meal, and the mixing percentages of LP/NPH were 75/ 25, 50/50, 25/75, 0/100. Results PPG was lower in the LP + NPH combination-therapy than that in the R, NPH, LP monotherapy. The PPG was improved most successfully and hypoglycemia was less frequent with the mixing percentage 50/50 or 75/25. Conclusions We concluded that, compared with R and other mixing percentages of LP and NPH, mealtime injection of LP and NPH combination therapies using mixing percentage of 75/ 25 or 50/50 results in better postprandial glucose levels with less frequent hypoglycemia as well.

Original languageEnglish
Pages (from-to)1003-1008
Number of pages6
JournalJapanese Pharmacology and Therapeutics
Volume30
Issue number12
Publication statusPublished - 2002 Jan 1

Keywords

  • Hypoglycemia
  • Intensive insulin therapy
  • Postprandial hyperglycemia
  • Short-acting insulin analog lispro

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The successful method of replacing human regular insulin with short-acting insulin analog lispro: Treatment with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime'. Together they form a unique fingerprint.

  • Cite this